Cardiovascular Drugs — MCQs

Cardiovascular Drugs Indian Medical PG Practice Questions and MCQs

Question 1021: Which class of drugs blocks endothelin receptors and is used as first-line therapy for pulmonary arterial hypertension?

A. Endothelin receptor antagonists (Correct Answer)
B. Beta-blockers
C. Calcium channel blockers
D. Phosphodiesterase-5 inhibitors

Explanation: ***Endothelin receptor antagonists*** - These drugs, such as **bosentan**, **ambrisentan**, and **macitentan**, specifically block the effects of endothelin, a potent **vasoconstrictor** and **smooth muscle proliferator**, leading to pulmonary vasodilation. - They are considered a **first-line therapy**, especially in patients with **WHO functional class II and III** pulmonary arterial hypertension (PAH). - These agents target the endothelin pathway, one of the three key pathways (endothelin, nitric oxide, prostacyclin) implicated in PAH pathophysiology. *Beta-blockers* - **Beta-blockers** are generally **contraindicated** in PAH because they can worsen right ventricular function and reduce cardiac output. - They are used to treat conditions like systemic hypertension or coronary artery disease, not PAH. *Calcium channel blockers* - While certain **calcium channel blockers** (e.g., nifedipine, diltiazem, amlodipine) are used in a small subset of PAH patients who are **vasoreactive** (respond positively to acute vasodilator testing), they do not block endothelin receptors. - Their use is limited to about 5-10% of patients with idiopathic PAH who demonstrate acute vasoreactivity. *Phosphodiesterase-5 inhibitors* - **Phosphodiesterase-5 (PDE5) inhibitors** like **sildenafil** and **tadalafil** are also first-line agents for PAH and are very effective, but they work by enhancing the nitric oxide pathway, **not by blocking endothelin receptors**. - These drugs enhance the effects of nitric oxide through increased cGMP, leading to **pulmonary vasodilation**.

Question 1022: Which class of drugs is the first-line therapy for treating hypercholesterolemia?

A. Statins (Correct Answer)
B. Bile acid sequestrants
C. Fibrates
D. Niacin

Explanation: ***Statins*** - **Statins** are considered **first-line therapy** for hypercholesterolemia due to their potent reduction of **LDL-C**, proven cardiovascular benefits, and excellent safety profile [1]. - They work by inhibiting **HMG-CoA reductase**, the rate-limiting enzyme in cholesterol synthesis, primarily in the liver [1]. *Bile acid sequestrants* - **Bile acid sequestrants** are typically **second-line agents** or used in combination therapy when statins are insufficient or contraindicated [2]. - They reduce LDL-C by binding bile acids in the gut, thereby increasing the hepatic synthesis of bile acids from cholesterol. *Fibrates* - **Fibrates** are primarily used to treat **hypertriglyceridemia** and are less effective at lowering LDL-C compared to statins [2]. - They activate **PPAR-alpha**, leading to increased lipoprotein lipase activity and reduced hepatic triglyceride synthesis. *Niacin* - **Niacin** (nicotinic acid) can lower LDL-C, raise HDL-C, and reduce triglycerides, but its use is limited by common side effects like **flushing** and hepatotoxicity [2]. - Due to these side effects and the advent of more effective and well-tolerated drugs, niacin is rarely used as first-line therapy.

Question 1023: Which of the following is a common side effect of angiotensin-converting enzyme (ACE) inhibitors?

A. Bradycardia
B. Dry cough (Correct Answer)
C. Hypoglycemia
D. Constipation

Explanation: ***Dry cough*** - This is a well-known side effect of ACE inhibitors, occurring in up to 20% of patients. It is thought to be caused by the accumulation of **bradykinin** and **substance P** in the respiratory tract, as ACE is responsible for their degradation. - The cough is typically non-productive, persistent, and resolves upon discontinuation of the medication. *Bradycardia* - **Bradycardia**, or a slow heart rate, is not a common side effect of ACE inhibitors. - ACE inhibitors primarily work by reducing systemic vascular resistance and blood pressure, with minimal direct effect on heart rate. *Hypoglycemia* - **Hypoglycemia**, or low blood sugar, is not typically associated with ACE inhibitor use. - While some medications can affect glucose metabolism, ACE inhibitors do not directly cause hypoglycemia. *Constipation* - **Constipation** is not a common side effect of ACE inhibitors. - Gastrointestinal side effects are generally mild and less frequent with ACE inhibitors compared to some other drug classes.

Question 1024: A 70-year-old female with atrial fibrillation requires rate control. Which class of drug is considered first-line therapy for rate control in atrial fibrillation?

A. Calcium channel blockers
B. Beta-blockers (Correct Answer)
C. ACE inhibitors
D. Diuretics

Explanation: ***Beta-blockers*** - Are considered **first-line agents** for rate control in **atrial fibrillation**, along with non-dihydropyridine calcium channel blockers. - They work by blocking **beta-adrenergic receptors**, thereby decreasing **AV nodal conduction** and reducing ventricular rate. - Particularly preferred in patients with **heart failure with reduced ejection fraction**, **ischemic heart disease**, or **hyperthyroidism**. - Examples include **metoprolol**, **bisoprolol**, and **esmolol** (for acute settings). *Calcium channel blockers* - **Non-dihydropyridine calcium channel blockers** (diltiazem, verapamil) are also **first-line agents** for rate control in atrial fibrillation. - They are often preferred in patients with **COPD** or **asthma** where beta-blockers are contraindicated. - Should be **avoided** in patients with **heart failure with reduced ejection fraction** as they can worsen cardiac function. - Both drug classes (beta-blockers and CCBs) are considered equally effective for rate control, with choice depending on patient-specific factors. *ACE inhibitors* - Primarily used for managing **hypertension**, **heart failure**, and preventing **cardiovascular remodeling**. - They do not directly control **heart rate** in atrial fibrillation and are not indicated for rate control. - May have a role in **rhythm control** by reducing atrial remodeling, but this is not their primary indication. *Diuretics* - Primarily used to reduce **fluid overload** and manage **hypertension** and **heart failure** by increasing urine output. - They do not directly affect the **heart rate** or AV nodal conduction and are not used for rate control in atrial fibrillation. - May be used as **adjunctive therapy** in patients with volume overload.

Question 1025: Which adrenergic receptor subtype is targeted by beta-blockers like propranolol to lower blood pressure and manage angina?

A. Alpha-1
B. Alpha-2
C. Beta-1 (Correct Answer)
D. Beta-2

Explanation: ***Beta-1*** - **Beta-1 adrenergic receptors** are primarily located in the **heart**, and their blockade leads to decreased heart rate, contractility, and ultimately, lower blood pressure and reduced myocardial oxygen demand in angina [1], [2]. - While propranolol is a non-selective beta-blocker, its cardiovascular therapeutic effects are predominantly mediated through **beta-1 receptor blockade** in the heart [2]. *Alpha-1* - **Alpha-1 adrenergic receptors** are found in **vascular smooth muscle** and mediate **vasoconstriction** when activated. - Blocking these receptors, as with prazosin, would cause **vasodilation** and a drop in blood pressure, but this is not the primary mechanism of action for propranolol [2]. *Alpha-2* - **Alpha-2 adrenergic receptors** are typically located presynaptically, where they inhibit **norepinephrine release**, and centrally, where they can reduce sympathetic outflow. - Drugs like clonidine target these receptors to lower blood pressure, which is a mechanism distinct from beta-blockers. *Beta-2* - **Beta-2 adrenergic receptors** are predominantly found in **bronchial smooth muscle** and **vascular smooth muscle**, mediating bronchodilation and vasodilation, respectively. - Blocking these receptors, as a non-selective beta-blocker like propranolol does, can lead to adverse effects like **bronchoconstriction** in asthmatic patients, but it is not the primary target for lowering blood pressure or treating angina.

Question 1026: What is the primary mechanism of action of digoxin in the treatment of heart failure?

A. Inhibition of angiotensin II receptor
B. Inhibition of Na+/K+ ATPase (Correct Answer)
C. Inhibition of aldosterone secretion
D. Inhibition of beta-adrenergic receptors

Explanation: ***Inhibition of Na+/K+ ATPase*** - Digoxin directly inhibits the **sodium-potassium ATPase pump** in cardiac muscle cells, leading to an increase in intracellular sodium. - This increase in intracellular sodium then reduces the activity of the **sodium-calcium exchanger**, resulting in higher intracellular calcium levels and increased myocardial contractility (positive inotropy). *Inhibition of angiotensin II receptor* - This is the mechanism of action for **angiotensin receptor blockers (ARBs)**, which are used in heart failure to reduce vasoconstriction and aldosterone release. - Digoxin does not directly interact with the **renin-angiotensin-aldosterone system** at the receptor level. *Inhibition of aldosterone secretion* - Aldosterone secretion is primarily inhibited by medications like **ACE inhibitors** and **ARBs**, or directly by aldosterone antagonists such as spironolactone. - Digoxin does not have a direct effect on the **adrenal gland's production** of aldosterone. *Inhibition of beta-adrenergic receptors* - This is the primary mechanism of action of **beta-blockers**, which are used in heart failure to reduce heart rate, myocardial oxygen demand, and remodeling. - Digoxin has a **positive inotropic effect** and does not block beta-adrenergic receptors; in fact, it can have some vagomimetic effects that slow heart rate.

Question 1027: Which of the following enzymes is inhibited by statins to lower cholesterol levels?

A. HMG-CoA reductase (Correct Answer)
B. Acetyl-CoA carboxylase
C. Fatty acid synthase
D. Citrate lyase

Explanation: ***HMG-CoA reductase*** * Statins (HMG-CoA reductase inhibitors) competitively block this enzyme, which is the **rate-limiting step** in cholesterol biosynthesis in the liver. * By inhibiting HMG-CoA reductase, statins reduce the synthesis of **mevalonate** and subsequently cholesterol, leading to a decrease in circulating LDL-C. *Acetyl-CoA carboxylase* * This enzyme is involved in **fatty acid synthesis**, not cholesterol synthesis. * It catalyzes the carboxylation of **acetyl-CoA to malonyl-CoA**, a key step in fatty acid elongation. *Fatty acid synthase* * This is a multienzyme complex responsible for the **synthesis of long-chain fatty acids** from acetyl-CoA and malonyl-CoA. * It plays no direct role in the synthesis of cholesterol. *Citrate lyase* * This enzyme is involved in the **synthesis of acetyl-CoA** from citrate in the cytoplasm, which can then be used for fatty acid or cholesterol synthesis. * While it provides a precursor for cholesterol, it is **not the direct rate-limiting step** targeted by statins.

Question 1028: Which antihypertensive drug is known for blocking the angiotensin II receptor (AT1) and reducing vasoconstriction?

A. Losartan (Correct Answer)
B. Amlodipine
C. Hydralazine
D. Propranolol

Explanation: ***Losartan*** - Losartan is an **angiotensin receptor blocker (ARB)**, specifically blocking the **AT1 receptor** to prevent angiotensin II from binding. - This action leads to **vasodilation**, reduced aldosterone secretion, and decreased blood pressure, without the cough side effect associated with ACE inhibitors. *Amlodipine* - Amlodipine is a **calcium channel blocker** that primarily causes **vasodilation** by relaxing vascular smooth muscle. - Its mechanism involves inhibiting the influx of calcium ions into vascular smooth muscle cells, not blocking angiotensin II receptors. *Hydralazine* - Hydralazine is a **direct arterial vasodilator** that acts to relax smooth muscle in the arterioles. - Its mechanism of action is not related to the renin-angiotensin-aldosterone system (RAAS) but rather to directly reducing peripheral vascular resistance. *Propranolol* - Propranolol is a **non-selective beta-blocker** that reduces blood pressure by decreasing heart rate, myocardial contractility, and renin release. - It does not directly block angiotensin II receptors but can indirectly affect the RAAS by reducing renin secretion.

Question 1029: In a patient taking amiodarone, which factor most contributes to its potential to cause thyroid dysfunction?

A. High iodine content of amiodarone (Correct Answer)
B. Direct thyroid toxicity
C. Inhibition of TSH secretion
D. Inhibition of peripheral T4 to T3 conversion

Explanation: ***High iodine content of amiodarone*** - Amiodarone contains approximately **37% iodine by weight**, leading to a significant daily iodine load that can disrupt normal thyroid function. - This excessive iodine can induce both **hypothyroidism (Wolff-Chaikoff effect)** and **hyperthyroidism (Jod-Basedow effect)** in susceptible individuals. *Direct thyroid toxicity* - While amiodarone can cause direct cytotoxic effects on thyroid cells, this is a **less prominent mechanism** compared to its iodine content in causing dysfunction. - **Amiodarone-induced destructive thyroiditis** (Type 2 AIT) involves direct thyroid damage and release of preformed hormones, but the initial trigger for widespread dysfunction is often the iodine. *Inhibition of TSH secretion* - Amiodarone does not primarily inhibit **TSH secretion**; in fact, TSH levels may be altered as a *result* of amiodarone's effects on thyroid hormone synthesis or release. - **Hypothyroidism** caused by amiodarone is typically characterized by **elevated TSH** due to reduced thyroid hormone production. *Inhibition of peripheral T4 to T3 conversion* - Amiodarone does inhibit the **peripheral conversion of T4 to T3** by blocking the 5'-deiodinase enzyme. - While this contributes to changes in thyroid hormone levels (e.g., elevated T4, reduced T3), it is **not the primary factor** responsible for the wide range of amiodarone-induced thyroid dysfunctions (hyper- and hypothyroidism), which are more directly linked to its high iodine load.

Question 1030: Which of the following pharmacological agents can be used to induce stress during myocardial radionucleotide perfusion imaging?

A. Adenosine
B. All of the options (Correct Answer)
C. Dobutamine
D. Dipyridamole

Explanation: ***All of the options*** - **Dipyridamole**, **adenosine**, and **dobutamine** are all pharmacological agents commonly used to induce stress for myocardial perfusion imaging. - They produce coronary vasodilation (dipyridamole, adenosine) or increased myocardial oxygen demand (dobutamine) to unmask **ischemia**. *Dipyridamole* - **Dipyridamole** inhibits adenosine reuptake and phosphodiesterase, leading to increased extracellular adenosine, causing **coronary vasodilation**. - Its use can result in a steal phenomenon where blood is diverted from stenosed areas to healthy vessels. *Adenosine* - **Adenosine** is a direct vasodilator of coronary arteries, creating a disparity in blood flow between normal and stenotic vessels. - It has a very short half-life (~10 seconds), allowing for rapid onset and offset of its effects. *Dobutamine* - **Dobutamine** is a beta-1 adrenergic agonist that increases heart rate and myocardial contractility, thereby increasing myocardial oxygen demand. - It is often used as a stress agent when patients have contraindications to vasodilators.

Practice by Chapter

Antihypertensive Agents

Practice Questions

Drugs for Heart Failure

Practice Questions

Antiarrhythmic Drugs

Practice Questions

Antianginal Agents

Practice Questions

Lipid-Lowering Drugs

Practice Questions

Anticoagulants and Antiplatelet Drugs

Practice Questions

Thrombolytic Agents

Practice Questions

Drugs Used in Pulmonary Hypertension

Practice Questions

Drugs Used in Shock

Practice Questions

Cardiovascular Effects of Non-Cardiovascular Drugs

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free